Naples

• Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negativ … Recruiting
  2024-515063-66-00 4 2021-03-30 Early stage classical Hodgkin Lymphoma (cHL) without bulky lesions and
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• “A phase II, single arm study investigating neoadjuvant plus adjuvant treatment with Cemiplimab in surgically resectable, high risk stage II … Recruiting
  2024-515204-39-00 4 2021-02-10 surgically resectable, high risk stage III/IV (M0) Cutaneaous Squamous
• Randomized phase III trial on NIraparib-Dostarlimab vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peri … Recruiting
  2024-516649-38-00 5 2020-12-01 Recurrent ovarian, fallopian tube or primary peritoneal cancer
• The study is aimed at evaluating the feasibility of a hypomethylating treatment combined with hematopoietic stem cell transplantation in com … Recruiting
  2023-510515-19-00 5 2020-11-27 Higher-risk-myelodysplastic syndromes
• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination with Cemiplimab in Adult Patients with Recurrent Ovarian Cancer or Other … Recruiting
  2024-510783-23-00 7 2020-10-29 Fallopian Tube Cancer
• NeoAspMet - Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced recta … Recruiting
  2024-519007-10-00 10 2020-10-22 Locally advanced stage II/III rectal cancer
• “A phase II randomized non-comparative study, with NEOadjuvant plus adjuvant Therapy with combination or sequence of vemurafenib, cobImetini … Recruiting
  2024-516659-41-00 4 2020-10-12 high-risk, surgically resectable BRAF mutated and wild-type Melanoma
• FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting
  2024-510579-40-00 9 2020-10-07 Rhabdoyosarcoma
• A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or … Recruiting
  2023-504888-16-00 9 2020-10-05 Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressi
• RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line … Recruiting
  2024-518623-30-00 6 2020-10-01 metastatic castration resistant prostate cancer without mutations of B
• Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting
  2023-510433-29-00 5 2020-09-24 Favorable-intermediate-risk Acute Myeloid Leukemia
• Effect of metyrapone on cardiovascular risk factors in patients with adrenal incidentalomas and subclinical/mild Cushing's syndrome Recruiting
  2024-518932-34-00 6 2020-09-22 patients with adrenal incidentalomas and subclinical/mild Cushing’s sy
• An international trial for children with atypical teratoid/rhabdoid tumours (ATRT) Recruiting
  2022-501456-28-00 5 2020-07-20 atypical teratoid/rhabdoid tumours (ATRT)
• A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) … Recruiting
  2024-516612-16-00 4 2020-06-17 gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)
• Pan tumor Roll Over Study Recruiting
  2023-506914-32-00 4 2020-05-05 Pan tumor
• Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-sm … Recruiting
  2024-517200-10-00 4 2020-01-31 Advanced non-small-cell lung cancer
• A study evaluating the safety and efficacy of ponatinib for the treatment of recurrent or refractory leukemias or solid tumors in children Recruiting
  2023-509699-41-00 9 2019-11-22 Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
• A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA Recruiting
  2023-507883-38-00 5 2019-11-18 Systemic Juvenile Idiopathic Arthritis
• Trial aimed at examinate the functionality and effectiveness of the drug "IO" in adult patients with a rare form of cancer that affect the c … Recruiting
  2023-510516-39-00 4 2019-10-30 Acute B-cell Lymphoblastic Leukemia with minimal residual positive dis
• Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally adva … Recruiting
  2024-513372-18-00 4 2019-10-18 Pre- and post-menopausal women with HR+/HER2- LABC or MBC whose diseas
• Phase 2a Study of Luspatercept in Pediatric Participants With Beta (β)-Thalassemia Recruiting
  2022-502499-22-00 4 2019-10-15 Beta (β) Thalassemia
• A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatoce … Recruiting
  2023-507689-26-00 5 2019-10-07 Histologically or cytologically confirmed Locoregional Hepatocellular
• A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X) Recruiting
  2023-506131-15-00 5 2019-09-10 Juvenile Idiopathic Arthritis

Showing 577–600 of 1,177 trials